focus -WSS

focus

author：knowledge 2025-09-06 08:39:04 - browse：76

Erik Tokat -- biotech JPM coverage from STAT — Eric Tokat is co-president of investment banking at Centerview Partners. Courtesy Centerview Partners

SAN FRANCISCO — Eric Tokat, biotech’s most prolific dealmaker, believes 2024 will be another strong year for acquisitions, driven by Big Pharma’s need to restock pipelines with medicines that can generate sales in the coming years.

That’s not idle speculation. It’s perhaps as close to a guarantee one can get in biotech. Last year, Tokat’s advisory firm, Centerview Partners, was involved in 19 of the 23 biotech transactions valued at $1 billion or more. Two more acquisitions of Centerview clients — Harpoon Therapeutics and Ambrx Biopharma — were announced Monday morning.

“I’m not sure if we’re going to have 23 deals or 25 deals, but I think it’s going to be a good year,” said Tokat, speaking to STAT over coffee on the sidelines of the J.P. Morgan Healthcare Conference.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： BioMarin wins approval for gene therapy to treat hemophilia A
Next article： Elizabeth Holmes banned from government health programs

focus

WSS

EU regulator recommends expanding Mounjaro approval to obesity

Affirmative action in medical school literally saved lives

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Eli Lilly, Pfizer, and others want in on the online prescription market

Think you might have Covid

EU regulator recommends expanding Mounjaro approval to obesity

explore

focus

Wikipedia

New air purifier tech could be key to improving indoor air quality

Cancer drug shortages should be causing more outrage

Supreme Court strikes down use of affirmative action

New air purifier tech could be key to improving indoor air quality

Medicare proposal to cover medical devices draws a mixed reaction

Readout Newsletter: BridgeBio, Madrigal, and Silicon Valley Bank

Supreme Court strikes down use of affirmative action

United colonoscopy coverage change 'may cost lives,' doctors say

Apple is now the first public company to be valued at $3 trillion

FDA clears AI tool for detecting skin cancer

focus

United colonoscopy coverage change 'may cost lives,' doctors say

Dewpoint Therapeutics lays off staff after losing partnerships

Malaria cases in Florida and Texas: Here’s what you need to know

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

How digital therapeutics firms are pivoting after Pear's bankruptcy

EU regulator recommends expanding Mounjaro approval to obesity

focus

leisure time

focus

focus